GlassScriptPhysician profile
Jacquelyn M Terry
NPI 1245772292
$8,245.00
in general payments reported to CMS, 2019-2025
24 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $601 · 2023: $1,710 · 2024: $2,418 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,731.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,108.56 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,057.14 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $804.80 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $692.02 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $649.74 | 2023-2025 | Auvelity |
| Corium, LLC | $638.83 | 2022-2025 | Azstarys |
| Validus Pharmaceuticals LLC | $532.11 | 2021-2025 | Equetro, Raldesy |
| Alkermes, INC. | $359.17 | 2021-2025 | Lybalvi, Aristada |
| Collegium Pharmaceutical, INC. | $343.54 | 2025 | Jornay Pm |
| Lundbeck LLC | $301.94 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $301.32 | 2022-2024 | Rexulti, Abilify Mycite |
| Noven Therapeutics, LLC | $271.49 | 2024-2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $191.54 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $184.65 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $137.72 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $135.21 | 2021-2025 | Trintellix |
| Noven Pharmaceuticals, INC. | $124.74 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $103.41 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $88.28 | 2021 | |
| Tris Pharma INC | $76.36 | 2023-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $61.78 | 2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $44.25 | 2023-2025 | Spravato |
| Neurocrine Biosciences, INC. | $18.93 | 2024 | Ingrezza |
| Sage Therapeutics, LLC | $17.47 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.